SAT0193 Early discontinuation of first line biological treatment with etanercept in patients with rheumatoid arthritis: results from the italian gisea registry

Abstract

Background:Tumor necrosis factor-α inhibitors (TNFi) are usually the first biologic drugs employed in rheumatoid arthritis (RA) after failure of conventional disease-modifying antirheumatic drugs (DMARDs). Retention rate is a useful surrogate...